Størset E - Search Results

1

Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling.

Størset E, Holford N, Hennig S, Bergmann TK, Bergan S, Bremer S, Åsberg A, Midtvedt K, Staatz CE. Størset E, et al. Br J Clin Pharmacol. 2014 Sep;78(3):509-23. doi: 10.1111/bcp.12361. Br J Clin Pharmacol. 2014. PMID: 25279405 Free PMC article.

2

Importance of hematocrit for a tacrolimus target concentration strategy.

Størset E, Holford N, Midtvedt K, Bremer S, Bergan S, Åsberg A. Størset E, et al. Eur J Clin Pharmacol. 2014 Jan;70(1):65-77. doi: 10.1007/s00228-013-1584-7. Epub 2013 Sep 27. Eur J Clin Pharmacol. 2014. PMID: 24071959 Free PMC article.

3

Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose.

Staatz CE, Størset E, Bergmann TK, Hennig S, Holford N. Staatz CE, et al. Among authors: storset e. Br J Clin Pharmacol. 2015 Dec;80(6):1475-6. doi: 10.1111/bcp.12729. Epub 2015 Sep 15. Br J Clin Pharmacol. 2015. PMID: 26235203 Free PMC article. No abstract available.

4

The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A. Størset E, et al. Br J Clin Pharmacol. 2017 Jul;83(7):1457-1465. doi: 10.1111/bcp.13248. Epub 2017 Feb 27. Br J Clin Pharmacol. 2017. PMID: 28146606 Free PMC article. Clinical Trial.

5

Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A. Størset E, et al. Br J Clin Pharmacol. 2017 Jun;83(6):1357-1358. doi: 10.1111/bcp.13276. Epub 2017 Apr 3. Br J Clin Pharmacol. 2017. PMID: 28374426 Free PMC article. No abstract available.

6

Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A. Størset E, et al. Br J Clin Pharmacol. 2017 Jun;83(6):1350-1352. doi: 10.1111/bcp.13188. Epub 2016 Dec 22. Br J Clin Pharmacol. 2017. PMID: 28008657 Free PMC article. No abstract available.

7

Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation.

Åsberg A, Midtvedt K, van Guilder M, Størset E, Bremer S, Bergan S, Jelliffe R, Hartmann A, Neely MN. Åsberg A, et al. Among authors: storset e. Transpl Int. 2013 Dec;26(12):1198-207. doi: 10.1111/tri.12194. Epub 2013 Oct 15. Transpl Int. 2013. PMID: 24118301 Free PMC article.

8

Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study.

Størset E, Åsberg A, Skauby M, Neely M, Bergan S, Bremer S, Midtvedt K. Størset E, et al. Transplantation. 2015 Oct;99(10):2158-66. doi: 10.1097/TP.0000000000000708. Transplantation. 2015. PMID: 25886918 Free PMC article. Clinical Trial.

9

High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation.

Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A. Egeland EJ, et al. Among authors: storset e. Transplantation. 2017 Aug;101(8):e273-e279. doi: 10.1097/TP.0000000000001796. Transplantation. 2017. PMID: 28452920

10

Prediction of Fat-Free Mass in Kidney Transplant Recipients.

Størset E, von Düring ME, Godang K, Bergan S, Midtvedt K, Åsberg A. Størset E, et al. Ther Drug Monit. 2016 Aug;38(4):439-46. doi: 10.1097/FTD.0000000000000305. Ther Drug Monit. 2016. PMID: 27019101

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters